Novo Nordisk has reported post hoc findings from the Phase III REDEFINE 1 trial evaluating its investigational combination therapy CagriSema in adults with overweight or obesity.

The double-blind, placebo- and active-controlled study (NCT05567796) evaluated subcutaneous CagriSema against semaglutide 2.4mg, cagrilintide 2.4mg, and placebo across 68 weeks in 3,417 patients with obesity or overweight and comorbidities.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Presented at ObesityWeek 2026 in Washington, DC, the retrospective analyses evaluated individual weight loss trajectories, early treatment response rates, and patient-reported physical and psychosocial outcomes associated with the dual-action therapy.

The post hoc assessment showed that 67.8% of participants receiving CagriSema achieved early responder status, defined as losing at least 5% of their baseline body weight by week eight.

Early responders achieved an observed mean weight reduction of 25.4% at week 68, compared with a 17.8% mean weight loss among delayed responders, who lost under 5% at week eight.

Furthermore, 73.3% of early responders attained at least 20% total weight reduction at week 68, whereas 37.2% of delayed responders reached that threshold. Women showed higher early response rates than men.

Novo executive vice president, chief scientific officer and research & development head Martin Holst Lange said: “Obesity is a chronic disease, and people respond to treatment differently and over different timeframes.

“That is why we continue to study the REDEFINE 1 data in greater depth. In this post hoc analysis, most people treated with CagriSema 2.4mg/2.4mg were early responders, meaning they lost at least 5% of their body weight within the first eight weeks of treatment.

“Together with the patient-reported physical function results, this research adds to the growing evidence base from the REDEFINE clinical programme.”

Patient-reported outcomes were measured using the Impact of Weight on Quality of Life-Lite Clinical Trials Version questionnaire.

At week 68, 73.1% of CagriSema recipients reported meaningful improvements in physical function compared to 49.1% on placebo.

Regarding safety, adverse events led to treatment discontinuation in 5.9% of CagriSema recipients versus 3.5% with placebo.

Gastrointestinal effects occurred in 79.6% of patients on CagriSema compared to 39.9% on placebo, predominantly presenting as mild-to-moderate, transient nausea, constipation, and vomiting.

CagriSema combines cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA).

Novo Nordisk submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) in December 2025, with an agency decision expected in the fourth quarter of 2026.

In July 2026, the company reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy of investigational denecimig (Mim8) in patients with haemophilia A.